Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines

By Shitara Kohei  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 787-793

Springer Publishing Company

Access to resources Recommend Favorite

Phase II study of combination chemotherapy with irinotecan and cetuximab for pretreated metastatic colorectal cancer harboring wild-type KRAS

By Shitara Kohei   Yokota Tomoya   Takahari Daisuke   Shibata Takashi   Ura Takashi   Utsunomiya Setsuo   Inaba Yoshitaka   Yamaura Hidekazu   Sato Yozo   Najima Mina   Kawai Hiroki   Tajika Masahiro   Sawaki Akira   Yatabe Yasushi   Muro Kei  

Investigational New Drugs, Vol. 29, Iss. 4, 2011-08 ,pp. : 688-693

Springer Publishing Company

Access to resources Recommend Favorite

Cetuximab: In the Treatment of Metastatic Colorectal Cancer

By Reynolds N.A.   Wagstaff A.J.  

Drugs, Vol. 64, Iss. 1, 2004-01 ,pp. : 109-118

Adis International

Access to resources Recommend Favorite

No Duplicate KRAS Mutation is Identified on the Same Allele in Gastric or Colorectal Cancer Cells with Multiple KRAS Mutations

By Kimura K   Nagasaka T   Hoshizima N   Sasamoto H   Notohara K   Takeda M   Kominami K   Iishii T   Tanaka N   Matsubara N  

The Journal of International Medical Research, Vol. 35, Iss. 4, 2007-07 ,pp. : 450-457

Field House Publishing

Access to resources Recommend Favorite

Cetuximab Inhibits Gastric Cancer Growth in vivo, Independent of KRAS Status

By  

Current Cancer Drug Targets, Vol. 14, Iss. 2, 2014-02 ,pp. : 217-224

Bentham Science Publishers

Access to resources Recommend Favorite